Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Merck, Truist
Merck downgraded by Truist to hold over growth concerns
Truist has downgraded Merck (NYSE:MRK) to hold from buy, citing upcoming loss of market exclusivity and continuing headwinds for its Gardisil vaccine. "While we believe MRK will navigate through the environment,
Truist Financial downgrades Merck & Company (MRK) to a Hold
Truist Financial analyst Srikripa Devarakonda downgraded Merck & Company (MRK – Research Report) to a Hold yesterday and set a price target
Truist Securities Downgrades Merck (MRK)
Fintel reports that on January 8, 2025, Truist Securities downgraded their outlook for Merck (NYSE:MRK) from Buy to Hold. Analyst Price Forecast Suggests 30.22% Upside As of December 23, 2024, the average one-year price target for Merck is $131.
2d
Merck's HPV vaccine gets China approval for men amid declining sales
Merck's human papillomavirus vaccine has been approved for men in China, it said on Wednesday, providing the U.S. drugmaker a ...
2d
Merck Gets China Nod on HPV Shot for Men Amid Sales Slump
China’s drug regulator approved Merck & Co.’s blockbuster HPV vaccine for use by men, opening a new untapped market for the ...
1d
Merck & Co. Inc. stock outperforms competitors despite losses on the day
The stock's fall snapped a two-day winning streak.
2d
on MSN
Merck says HPV vaccine for men approved by China's drug regulator
U.S. drugmaker Merck & Co said on Wednesday its human papillomavirus (HPV) vaccine for men has been approved by China's ...
BioSpace
1h
Pfizer’s Subcutaneous PD-1 Blocker Aces Phase III in Bladder Cancer, Carves Niche Versus Keytruda
If approved, Pfizer’s sasanlimab will distinguish itself from Merck’s blockbuster Keytruda as the first PD-1 inhibitor ...
3d
on MSN
WuXi Biologics to Sell Irish Vaccine Facility to Merck for $500 Million
WuXi Biologics’ move to sell the facility could strengthen the company’s cash flow and margins as it navigates global ...
Joplin Globe
2h
Atropos Health Collaborates with Merck for Rapid Evidence Generation to Accelerate Innovation for Life-Saving Treatments
Atropos Health Collaborates with Merck for Rapid Evidence Generation to Accelerate Innovation for Life-Saving Treatments ...
2d
Merck’s GARDASIL® Receives Expanded Approval for Males in China
GARDASIL is the first HPV vaccine approved for the prevention of certain HPV-related cancers and diseases in Chinese males ...
Brattleboro Reformer
21h
Natural wonders: Finding the 'magic of winter' at Merck Forest
Serenity may feel hard to come by these days, but the natural world still offers solace for those willing to seek it.
Bennington Banner
1d
Explore Merck Forest at night or by day with upcoming guided hikes
Merck Forest & Farmland Center will be hosting two upcoming events, an Animal Tracking Hike on Saturday, January 11 from 10 a ...
3d
WuXi Bio to Sell Vaccine Facility to Merck for $500 Million
WuXi Biologics Cayman Inc. will sell a vaccine facility in Ireland to Merck & Co. for about $500 million as the Chinese ...
24/7 Wall St. on MSN
2d
Merck Just Paid Investors: How Much Did They Receive?
Merck just rewarded its shareholders again with a dividend hike. This Dow stock has come with a quarterly dividend for almost ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
China
HPV vaccine
WuXi
Germany
Gardasil
Feedback